Fig. 2

Bioact®180 does not affect the nuclear localisation of DAF-16::GFP. (a) Representative images of worms that have (i) cytoplasmic and (ii) nuclear DAF-16::GFP localisation. Scale bars are 100 µm. (b) Worms were placed onto Bioact®180 supplemented NGM as L1s and the localisation of DAF-16::GFP observed at the L4 stage. (c) From these, 5 random L4 animals were transferred to a fresh Bioact®180 supplemented NGM plate and allowed to lay eggs and then removed. When these progeny were L4, DAF-16::GFP localisation was recorded. Black bars indicate cytoplasmic localisation and white bars show DAF-16::GFP located in the nucleus where it is able to activate the insulin signalling pathway. Grey bars show an intermediate localisation, whereby DAF-16::GFP is found in both the nucleus and cytoplasm. The negative control was NGM, a 0.2% DMSO vehicle control was included together with a 2% DMSO positive control. Strain, TJ356; n = 100 for all conditions